Trial Profile

Phase Ia trial of IMT002 in Type-1-diabetes-mellitus

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs D-methyldopa IM Therapeutics (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

29 Oct 2020 Results presented in a IM Therapeutics Media Release.
29 Oct 2020 Status changed from recruiting to completed, according to a IM Therapeutics media release.
07 Jul 2020 According to a IM Therapeutics media release, the company submitted an investigational new drug (IND) application in April and received FDA clearance to begin this trial in May.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com